Detalles de la búsqueda
1.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection.
Antimicrob Agents Chemother
; 64(7)2020 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32393496
2.
Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.
Antimicrob Agents Chemother
; 61(11)2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28807912
3.
Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
Antimicrob Agents Chemother
; 60(9): 5437-44, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27381392
4.
Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat".
Antimicrob Agents Chemother
; 62(1)2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29269431
5.
Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection.
J Clin Pharmacol
; 60(11): 1509-1518, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32621543
6.
Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.
Clin Pharmacokinet
; 57(3): 367-377, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28639229
7.
Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).
Arthritis Res Ther
; 16(5): 467, 2014 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25359150
Resultados
1 -
7
de 7
1
Próxima >
>>